It also targets ROS1 and ALK, with IC50 values ranging from 0.1 to 2 nM, while showing weaker inhibition of JAK2 and TNK2 (IC50 > 5 nM). The primary active metabolite, M5, exhibits similar ...
The study reviews the clinical diagnosis and treatment of CRC with rare genetic variations, including mutations, ...
This product class is being initially established through the launch of ALK-RET-ROS1 targeted FFPE RNA Fusion Reference Standards. These standards are highly-characterized, biologically-relevant, ...
Investment analysts at HC Wainwright reduced their Q1 2025 earnings per share estimates for Nuvalent in a report released on Monday, March 3rd. HC Wainwright analyst S. Ramakanth now anticipates that ...
So far, eight types of lung cancer gene mutations have been identified, including epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), ROS1, and KRAS. The PANAMutyper ROS1 ...
Its pipeline includes ROS1 NSCLC, ALK NSCLC and HER2 NSCLC. The company was founded by Matthew D. Shair in January 2017 and is headquartered in Cambridge, MA.
The European Commission (EC) has approved sugemalimab in combination with platinum-based chemotherapy for the first-line treatment of patients with metastatic NSCLC with no sensitizing EGFR mutations, ...
It also targets ROS1 and ALK, with IC50 values ranging from 0.1 to 2 nM, while showing weaker inhibition of JAK2 and TNK2 (IC50 > 5 nM). The primary active metabolite, M5, exhibits similar ...
It also targets ROS1 and ALK, with IC50 values ranging from 0.1 to 2 nM, while showing weaker inhibition of JAK2 and TNK2 (IC50 > 5 nM). The primary active metabolite, M5, exhibits similar inhibitory ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback